• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avantor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    7/17/26 4:44:13 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email
    avtr-20260714
    false000172248200017224822026-07-142026-07-140001722482us-gaap:CommonStockMember2026-07-142026-07-14


    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): July 14, 2026
    avantorlogoa08.jpg
    Avantor, Inc.
    (Exact name of registrant as specified in its charter)
    Delaware001-3891282-2758923
    (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
    Radnor Corporate Center, Building One, Suite 200
    100 Matsonford Road
    Radnor, Pennsylvania 19087
    (Address of principal executive offices, including zip code)
    (610) 386-1700
    (Registrant’s telephone number, including area code)
    Not Applicable
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:



    Title of each classTrading SymbolExchange on which registered
    Common Stock, $0.01 par valueAVTRNew York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




    Item 1.01 Entry into a Material Definitive Agreement
    On July 14, 2026 (the “Effective Date”), Avantor Funding, Inc. (the “Borrower”), a wholly owned subsidiary of Avantor, Inc. (the “Company”), entered into Amendment No. 15 to Credit Agreement (the “Credit Agreement Amendment”), which amended that certain Credit Agreement, originally dated as of November 21, 2017 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time prior to the Effective Date, the “Credit Agreement”), among Vail Holdco Sub LLC, the Borrower, each of the guarantors party thereto (the “Guarantors”), Goldman Sachs Bank USA, as administrative agent and collateral agent (the “Administrative Agent”), the swing line lender, a letter of credit issuer and as the Additional Incremental B-7 Euro Term Lender (as defined in the Credit Agreement Amendment), and the other lenders party thereto (the “Lenders”).
    Pursuant to the Credit Agreement Amendment, the Borrower obtained a €374,208,296.62 tranche of senior secured Euro-denominated term loans (the “Incremental B-7 Euro Term Loans”). The Incremental B-7 Euro Term Loans bear interest at a rate equal to the floating EURIBO Rate plus a spread of 2.00% per annum. The Incremental B-7 Euro Term Loans replaced and refinanced certain of the Borrower’s existing senior secured euro term loans, which had an interest rate equal to the floating EURIBO Rate plus a spread of 2.50% per annum, that were scheduled to mature on October 9, 2032.
    The final stated maturity of the Incremental B-7 Euro Term Loans is October 9, 2032. In addition, the Credit Agreement Amendment provides that in the event the Borrower prepays, replaces or refinances (including any such prepayment, replacement or refinancing effected through an amendment to the Credit Agreement Amendment) all or a portion of Incremental B-7 Euro Term Loans at any time prior to the six month anniversary of the Effective Date with any indebtedness under credit facilities in the form of similar term B loans that are broadly marketed or syndicated to banks and other institutional investors incurred primarily for the purpose of repaying, replacing or refinancing such Incremental B-7 Euro Term Loans at an effective yield that is less than the effective yield of such Incremental B-7 Euro Term Loans (excluding any indebtedness incurred in connection with a change of control or certain transformative acquisitions), a prepayment premium equal to 1.00% of the principal amount of such Incremental B-7 Euro Term Loans being prepaid or 1.00% of the principal amount of the Incremental B-7 Euro Term Loans outstanding immediately prior to such amendment will be imposed on the Borrower.
    The Incremental B-7 Euro Term Loans are guaranteed by the same subsidiaries of the Company that guarantee the existing credit facilities under the Credit Agreement. The Incremental B-7 Euro Term Loans and the guarantees thereof are secured by the same collateral of the Borrower and the Guarantors that secures the Borrower’s obligations under the Credit Agreement on a pari passu basis.
    In addition, the Administrative Agent has provided the Borrower and its affiliates with financial advisory, commercial banking and investment banking services for which they received customary fees and expenses.
    The foregoing is a summary of the material terms of the Credit Agreement Amendment, does not purport to be complete, and is qualified in its entirety by reference to the Credit Agreement Amendment, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated herein by reference.
    Item 2.03.    Creation of a Direct Financial Obligation under an Off-Balance Sheet Arrangement of Registrant.
    The information set forth in Item 1.01 is incorporated into this Item 2.03 by reference.



    Item 9.01.    Financial Statements and Exhibits.
    (d) Exhibits.
    Exhibit No.Description
    10.1
    Amendment No. 15 to Credit Agreement, dated as of July 14, 2026 (the “Credit Agreement Amendment”), which amended that certain Credit Agreement, originally dated as of November 21, 2017, among Vail Holdco Sub LLC, Avantor Funding, Inc., each of the guarantors, Goldman Sachs Bank USA, as administrative agent and collateral agent, the swing line lender, a letter of credit issuer and the Additional Incremental B-7 Euro Term Lender (as defined in the Credit Agreement Amendment) and the other lenders party thereto.
    104
    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL



    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Avantor, Inc.
    Date: July 17, 2026By:/s/ Claudius Sokenu
    Name:Claudius Sokenu
    Title:Executive Vice President, Chief Legal and Compliance Officer and Secretary (Duly Authorized Officer)

    Get the next $AVTR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    6/26/2026$10.50Mkt Perform
    Bernstein
    6/2/2026$7.00Underperform
    Wolfe Research
    5/15/2026$9.00Sector Perform
    RBC Capital Mkts
    3/6/2026$8.50Equal Weight → Underweight
    Barclays
    1/5/2026$12.00Outperform → In-line
    Evercore ISI
    12/17/2025$9.00Hold → Underperform
    Jefferies
    12/15/2025$13.00Buy → Neutral
    BofA Securities
    11/4/2025Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucier Gregory T was granted 25,270 shares and bought $83,200 worth of shares (10,000 units at $8.32), increasing direct ownership by 289% to 34,006 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/11/26 4:39:13 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Dingemans Simon bought $203,500 worth of shares (25,000 units at $8.14) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/5/26 7:44:08 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Lucier Gregory T bought $458,000 worth of shares (50,000 units at $9.16) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    2/23/26 8:53:53 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bernstein resumed coverage on Avantor with a new price target

    Bernstein resumed coverage of Avantor with a rating of Mkt Perform and set a new price target of $10.50

    6/26/26 9:17:41 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wolfe Research resumed coverage on Avantor with a new price target

    Wolfe Research resumed coverage of Avantor with a rating of Underperform and set a new price target of $7.00

    6/2/26 8:32:11 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    RBC Capital Mkts resumed coverage on Avantor with a new price target

    RBC Capital Mkts resumed coverage of Avantor with a rating of Sector Perform and set a new price target of $9.00

    5/15/26 8:27:36 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, VWR Dist. & Servs. Walker Corey covered exercise/tax liability with 3,010 shares, decreasing direct ownership by 0.78% to 384,535 units (SEC Form 4) to cover taxes

    4 - Avantor, Inc. (0001722482) (Issuer)

    6/22/26 5:07:34 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Murthy Mala was granted 25,270 shares, increasing direct ownership by 57% to 69,479 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/11/26 4:39:21 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Lucier Gregory T was granted 25,270 shares and bought $83,200 worth of shares (10,000 units at $8.32), increasing direct ownership by 289% to 34,006 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/11/26 4:39:13 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    SEC Filings

    View All

    Avantor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    7/17/26 4:44:13 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SD filed by Avantor Inc.

    SD - Avantor, Inc. (0001722482) (Filer)

    5/29/26 4:06:35 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    5/12/26 4:32:48 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product

    RADNOR, Pa., July 14, 2026 /PRNewswire/ -- Avantor (NYSE:AVTR), a leading global provider of mission-critical products and services to the life sciences and advanced technology industries, announced today the expansion of a collaboration between its NuSil® brand, a premier global manufacturer of high-purity silicones suitable for use in medical devices and drug-device combination products, and the Population Council, an international nonprofit research organization, to support the development of the Council's new three-month dapivirine vaginal ring for HIV prevention. NuSil originally partnered with the International Partnershi

    7/14/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026

    RADNOR, Pa., July 1, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Daylight Time. To hear a live audio webcast of the session, visit News & Events in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days.About Avanto

    7/1/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory

    RADNOR, Pa., May 19, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Gerard (Jerry) Porreca has joined the company as Executive Vice President, Quality and Regulatory. In this role, Mr. Porreca is responsible for leading quality assurance, quality systems and regulatory affairs globally across all Avantor's businesses.Mr. Porreca is an accomplished executive with deep quality, regulatory affairs, and compliance experience

    5/19/26 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Leadership Updates

    Live Leadership Updates

    View All

    Avantor® Appoints Simon Dingemans to its Board of Directors

    RADNOR, Pa., Dec. 18, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Simon Dingemans to its Board of Directors, effective January 2, 2026. Mr. Dingemans is an accomplished executive with extensive global leadership experience across healthcare, finance and strategic business transformation. He was previously the Chief Financial Officer of GlaxoSmithKline plc, a Partner at Goldman Sachs, and a Managing Dire

    12/18/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Sanjeev Mehra to its Board of Directors

    RADNOR, Pa., Dec. 4, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Sanjeev Mehra to its Board of Directors, effective immediately.   Mr. Mehra is Co-Founder and serves as Managing Partner of Periphas Capital LP, a private equity firm focused on investing in technology enabled businesses in services, consumer and industrial end markets. Prior to founding Periphas, Mr. Mehra spent over 30 years at Goldman,

    12/4/25 4:15:00 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Mary Blenn as Executive Vice President and Chief Operating Officer

    RADNOR, Pa., Nov. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Mary Blenn has been appointed to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Ms. Blenn will report to President and CEO Emmanuel Ligner and will lead the Company's manufacturing and supply chain operations. She will be responsible for aligning Avantor's manufacturing and logistics network wit

    11/10/25 8:30:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Financials

    Live finance-specific insights

    View All

    Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026

    RADNOR, Pa., July 1, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Daylight Time. To hear a live audio webcast of the session, visit News & Events in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days.About Avanto

    7/1/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports First Quarter 2026 Results

    Net sales of $1,581 millionNet income of $43 million; Adjusted EBITDA of $219 millionDiluted GAAP EPS of $0.06; adjusted EPS of $0.17Operating cash flow of $59 million; free cash flow of $25 millionReaffirms FY 2026 guidanceRADNOR, Pa., April 29, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal quarter ended March 31, 2026."First quarter results exceeded our expectations due to improved execution in Bioscience and Medtech Products, and we saw stabilization in VWR," said Emmanuel Ligner, President and Chi

    4/29/26 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026

    RADNOR, Pa., April 3, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2026 financial results before the market opens on Wednesday, April 29, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Daylight Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A repl

    4/3/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    11/14/24 1:28:33 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/9/24 3:22:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/7/24 4:09:12 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials